Etanercept ameliorates sarcoidosis arthritis and skin disease

Dinesh Khanna, Michael R. Liebling, James S. Louie

Research output: Contribution to journalArticlepeer-review

101 Scopus citations


Sarcoidosis is a systemic disorder of unknown etiology characterized by its pathological hallmark, the noncaseating granuloma. In granulomatous diseases, the proinflammatory peptide mediators, including tumor necrosis factor-α (TNF-α), are increased in the blood and fluids surrounding the activated macrophages. We describe a patient with chronic sarcoidosis arthropathy and lupus pernio resistant to corticosteroids and disease modifying antirheumatic agents, who responded to the addition of etanercept. We discuss the possible mechanisms of action of anti-TNF agents in granulomatous diseases and suggest that chronic, resistant sarcoidosis requires combination immunosuppressive therapy.

Original languageEnglish (US)
Pages (from-to)1864-1867
Number of pages4
JournalJournal of Rheumatology
Issue number8
StatePublished - Aug 1 2003


  • Etanercept
  • Sarcoidosis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Etanercept ameliorates sarcoidosis arthritis and skin disease'. Together they form a unique fingerprint.

Cite this